Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Molecular Partners Ag ADR (NQ: MOLN )

3.320 -0.420 (-11.23%)
Streaming Delayed Price Updated: 11:25 AM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,190
Open 3.670
Bid (Size) 3.410 (5)
Ask (Size) 3.660 (1)
Prev. Close 3.740
Today's Range 3.320 - 3.775
52wk Range 3.350 - 7.320
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Life Science Cares Launches in Switzerland
First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities 
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
From Molecular Partners
Via GlobeNewswire

Performance

YTD
-20.38%
-20.38%
1 Month
-14.21%
-14.21%
3 Month
-29.21%
-29.21%
6 Month
-14.98%
-14.98%
1 Year
-46.71%
-46.71%

More News

Read More
Molecular Partners Publishes Invitation to Annual General Meeting 2024
From Molecular Partners
Via GlobeNewswire
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
From Molecular Partners
Via GlobeNewswire
Earnings Scheduled For March 14, 2024
Via Benzinga
Molecular Partners Announces Dismissal of Class Action Lawsuit
From Molecular Partners
Via GlobeNewswire
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
From Molecular Partners
Via GlobeNewswire
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
From Molecular Partners
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
From Molecular Partners
Via GlobeNewswire
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
From Molecular Partners
Via GlobeNewswire
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
From Molecular Partners
Via GlobeNewswire
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
From Molecular Partners
Via GlobeNewswire
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
From Molecular Partners
Via GlobeNewswire
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
From Molecular Partners
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.